USGuidelineProposedModel providersDeployersHealth
FDA 2027 AI Guidance Plans
FDA 2027年AI监管指南计划
FDA·Published 2026-10-06·Checked by 管理员 on 2026-10-08
FDA has outlined its plans for issuing AI guidance documents in 2027, focusing on regulatory approaches for AI products in healthcare. Concurrently, Utah has announced an expansion of its AI regulatory sandbox program.
What it means for you
- Medical AI product providers must prepare for upcoming FDA regulatory requirements
Companies can leverage Utah's expanded regulatory sandbox to test innovative AI products
- A clear timeline and framework for medical AI approval and compliance will be established in 2027
What to do
ProductMonitor FDA's 2027 AI guidance plans and adjust product development strategies accordingly
ComplianceEvaluate opportunities to participate in Utah's AI regulatory sandbox
EveryoneEnsure existing medical AI products comply with upcoming regulatory requirements
Key dates
2026-10-06Published
Source documents
Coverage
Stories in the feed
Editorial summary, not legal advice; dates and status follow the original document. · Report a correction